Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder
- PMID: 18568072
- PMCID: PMC2416754
Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder
Abstract
The pathophysiology of obsessive-compulsive disorder (OCD) remains unknown. However, increasing attention has been paid to the putative role of the serotoninergic system, the strongest evidence being based on the widely demonstrated efficacy of serotonin (5HT) reuptake inhibitor antidepressants in the treatment of OCD. The therapeutic effects are correlated with changes in peripheral parameters of 5HT function, which have been found to be altered in OCD, suggesting the possibility of reduced 5HT reuptake capacity. This could reflect a compensatory mechanism presumably due to decreased availability of extracellular 5HT, as evidenced by data derived from direct assessment of central 5HT neurotransmission. The development of new neurochemical probes that explore the sensitivity of various 5HT receptor subtypes has provided precious information. m-Chlorophenylpyperazine (m-CPP), an agonist to 5HT1A, 5HT1D, and 5HT2C receptors, and which also blocks 5HT3 receptors, exacerbates OC symptoms. In contrast, neither MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine), a 5HT1A and 5HT2C receptor agonist, nor ipsapirone or buspirone, which acts as an agonist to 5HT1A receptors, have any effect on OC symptom severity. This suggests the potential implication of the 5HT1D receptor, as shown by the aggravation of OC manifestations in response to sumatriptan, a selective 5HT1D receptor agonist. The 5HT3 plays no specific role, given the lack of influence of the 5HT3 antagonist ondansetron, on OC symptom intensity. Further studies are required to elucidate the pharmacological molecular determinants of the putative 5HT1D receptor dysfunction.
Keywords: 5HT1D receptor agonists; obsessive-compulsive disorder; receptors; serotonin; serotonin reuptake inhibitors.
Figures

Similar articles
-
Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan.Eur Neuropsychopharmacol. 1998 Dec;8(4):325-8. doi: 10.1016/s0924-977x(97)00092-8. Eur Neuropsychopharmacol. 1998. PMID: 9928925
-
Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.Prog Neuropsychopharmacol Biol Psychiatry. 1999 Aug;23(6):1079-99. doi: 10.1016/s0278-5846(99)00051-2. Prog Neuropsychopharmacol Biol Psychiatry. 1999. PMID: 10621951 Clinical Trial.
-
Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.Biol Psychiatry. 1987 Jun;22(6):667-87. doi: 10.1016/0006-3223(87)90199-5. Biol Psychiatry. 1987. PMID: 3036259 Clinical Trial.
-
Potential use of drugs modulating 5HT activity in the treatment of anxiety.Gen Pharmacol. 1988;19(3):347-56. doi: 10.1016/0306-3623(88)90027-4. Gen Pharmacol. 1988. PMID: 2901381 Review.
-
[Present contribution of neurosciences to a new clinical reading of obsessive-compulsive disorder].Encephale. 2007 Mar-Apr;33(2):203-10. doi: 10.1016/s0013-7006(07)91551-1. Encephale. 2007. PMID: 17675916 Review. French.
Cited by
-
Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.BMC Psychiatry. 2013 Dec 23;13:344. doi: 10.1186/1471-244X-13-344. BMC Psychiatry. 2013. PMID: 24359174 Free PMC article. Clinical Trial.
-
Successful Early Lamotrigine and Aripiprazole Augmentation of Clomipramine in Severe Obsessive-compulsive Disorder.Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):604-608. doi: 10.9758/cpn.22.1044. Clin Psychopharmacol Neurosci. 2023. PMID: 37424428 Free PMC article.
-
Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial.Iran J Psychiatry. 2017 Jul;12(3):154-162. Iran J Psychiatry. 2017. PMID: 29062366 Free PMC article.
-
Adverse maternal environment affects hippocampal HTR2c variant expression and epigenetic characteristics in mouse offspring.Pediatr Res. 2022 Nov;92(5):1299-1308. doi: 10.1038/s41390-022-01962-8. Epub 2022 Feb 4. Pediatr Res. 2022. PMID: 35121849
-
The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder.Psychopharmacology (Berl). 2010 May;210(1):13-24. doi: 10.1007/s00213-010-1808-9. Epub 2010 Mar 19. Psychopharmacology (Berl). 2010. PMID: 20238210
References
-
- Akkal D, Bioulac B, Audin J, et al. Comparison of neuronal activity in the rostral supplementary and cingulate motor areas during a task with cognitive and motor demands. Eur J Neurosci. 2002;15:887–904. - PubMed
-
- Altemus M, Swedo SE, Leonard HL, et al. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry. 1994;51:794–803. - PubMed
-
- Ananth J, Pecknold JC, van den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol. 1981;5:257–62. - PubMed
-
- Antony MM, Downie F, Swinson RP. Diagnostic issues and epidemiology in obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, et al., editors. Obsessive-compulsive disorder. Theory, research, and treatment. New-York: Guilford Pr; 1998. pp. 3–32.
-
- Aouizerate B, Guehl D, Cuny E, et al. Pathophysiology of obsessive-compulsive disorder: a necessary link between the phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol. 2004;72:195–221. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources